Trust Size
$595M
Peak Price
$15.23
Current Price
$4.35
Return
-56.5%
Price Journey
What Happened
Nuvation Bio is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer, with a pipeline targeting drug resistance and limited efficacy in current oncology treatments.
Nuvation Bio went public in February 2021 through a merger with Panacea Acquisition Corp, a SPAC sponsored by EcoR1 Capital. Founded by veteran biotech executive David Hung (founder of Medivation, which was acquired by Pfizer for $14 billion), Nuvation Bio is advancing multiple oncology drug candidates including treatments for solid tumors and hematologic malignancies. The stock has traded below its SPAC price but has shown promise with clinical data readouts.
Timeline
2020-06-23
S-1 Registration Filed
SEC Filing Details
CIK Number
1811063
Total SEC Filings
361
State of Incorporation
DE
Last Filing Date
2026-03-03
Business Location
San Francisco, CA
Trust/Asset Size
$595M
Data sourced from SEC EDGAR Company Facts API and EFTS search index.
📄 SEC Filings
View all EDGAR filings for Nuvation Bio